| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15220 R62419 |
Bromley (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.67 [0.24;1.86] C excluded (control group) |
6/70 13/106 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15219 R62406 |
Bromley (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 | Small for gestation (calculated using gender-specific scales) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.48 [0.17;1.35] C | 6/70 13/80 | 19 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12549 R47239 |
Dreier (Levetiracetam), 2021 | Small for gestational age (birth weight below the 10th percentile for GA, sex and country) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.13 [0.92;1.39] | -/1,019 -/- | - | 1,019 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12618 R47566 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.75 [0.26;2.19] C excluded (control group) |
6/89 9/102 | 15 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12615 R47548 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Small for gestational age (weight for gestational age <10th percentile) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.13 [0.11;39.98] C | 6/89 0/14 | 6 | 89 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8986 R30513 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
7.00 [0.30;164.40] C excluded (control group) |
3/10 0/7 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8987 R30523 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 23.15 [1.05;509.05] C | 3/10 0/22 | 3 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9020 R30711 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.40 [1.11;1.77] C | 82/621 167,376/1,710,441 | 167,458 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9029 R30780 |
Bank (Levetiracetam) (Mixed indications), 2017 | Small for Gestational Age birthweight (<10th percentile) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.83 [0.16;20.71] C | 1/7 3/36 | 4 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9030 R30787 |
Kilic (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.33 [0.39;4.54] C excluded (control group) |
3/26 78/876 | 81 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9031 R30790 |
Kilic (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
1.22 [0.37;4.06] C excluded (control group) |
3/26 65,118/673,844 | 65,121 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9032 R30793 |
Kilic (Levetiracetam) (Controls unexposed, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.03 [0.31;3.43] C | 3/26 594/5,275 | 597 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8983 R30484 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.73 [0.12;59.97] C excluded (control group) |
0/13 2/173 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8984 R30496 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
2.00 [0.12;33.85] C excluded (control group) |
0/13 14,079/719,509 | 14,079 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8985 R30508 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.65 [0.10;28.29] C | 0/13 42/1,793 | 42 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 1.22 [0.96;1.54] | 168,129 | 1,855 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 2: Levetiracetam; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam) (Controls unexposed, sick; 5: Levetiracetam) (Controls unexposed, NOS; 6: Levetiracetam) (Mixed indications; 7: Levetiracetam) (Controls unexposed, sick) (Mixed indications; 8: Levetiracetam) (Controls unexposed, sick;
Asymetry test p-value = 0.7009 (by Egger's regression)
slope=0.1723 (0.1226); intercept=0.2275 (0.5644); t=0.4031; p=0.7009
excluded 8983, 8984, 9030, 9031, 8986, 12618, 15220